Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary Remove Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Summaries of opinion (20) Apply Summaries of opinion filter Withdrawn applications (85) Apply Withdrawn applications filter Orphan designations (258) Apply Orphan designations filter Direct healthcare professional communication (14) Apply Direct healthcare professional communication filter

Product number

Authorisation status

Authorised (477) Apply Authorised filter Refused (20) Apply Refused filter Withdrawn (82) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (13) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (73) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (12) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (20) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (4) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (2) Apply Yes filter

Referral type

Article 31 referrals (3) Apply Article 31 referrals filter Article 20 procedures (1) Apply Article 20 procedures filter Article 82 (1) Apply Article 82 filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (3) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (1) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (1) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Biosimilar Remove Biosimilar filter Generic Remove Generic filter Orphan medicine Remove Orphan medicine filter Accelerated assessment (93) Apply Accelerated assessment filter Additional monitoring (585) Apply Additional monitoring filter Conditional approval (80) Apply Conditional approval filter Exceptional circumstances (64) Apply Exceptional circumstances filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

684 results

Remove all filtersRemove all filters

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Medicine type Biosimilar Remove Biosimilar filter Generic Remove Generic filter Orphan medicine Remove Orphan medicine filter

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter

Sort by

List item

Human medicine European public assessment report (EPAR): Yesafili (updated)

aflibercept, Macular Edema; Retinal Vein Occlusion; Diabetic Retinopathy; Myopia, Degenerative; Diabetes Complications
Date of authorisation: 15/09/2023, , , Revision: 1, Authorised, Last updated: 04/12/2023
List item

Human medicine European public assessment report (EPAR): Leflunomide medac (updated)

leflunomide, Arthritis, Rheumatoid
Date of authorisation: 27/07/2010, , Revision: 19, Authorised, Last updated: 04/12/2023
List item

Human medicine European public assessment report (EPAR): Filgrastim Hexal (updated)

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 06/02/2009, , Revision: 24, Authorised, Last updated: 04/12/2023
List item

Human medicine European public assessment report (EPAR): Ziextenzo (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 22/11/2018, , Revision: 9, Authorised, Last updated: 04/12/2023
List item

Human medicine European public assessment report (EPAR): Clopidogrel Krka (updated)

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 23/09/2009, , Revision: 19, Authorised, Last updated: 04/12/2023
List item

Human medicine European public assessment report (EPAR): Fulphila (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 20/11/2018, , Revision: 12, Authorised, Last updated: 04/12/2023
List item

Human medicine European public assessment report (EPAR): Semglee (updated)

insulin glargine, Diabetes Mellitus
Date of authorisation: 23/03/2018, , Revision: 10, Authorised, Last updated: 01/12/2023
List item

Human medicine European public assessment report (EPAR): Ogivri (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 12/12/2018, , Revision: 11, Authorised, Last updated: 01/12/2023
List item

Human medicine European public assessment report (EPAR): Kirsty (previously Kixelle) (updated)

insulin aspart, Diabetes Mellitus
Date of authorisation: 05/02/2021, , , Revision: 4, Authorised, Last updated: 01/12/2023
List item

Human medicine European public assessment report (EPAR): Hulio (updated)

adalimumab, Hidradenitis Suppurativa; Psoriasis; Uveitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic
Date of authorisation: 17/09/2018, , Revision: 16, Authorised, Last updated: 01/12/2023
List item

Human medicine European public assessment report (EPAR): Dovprela (previously Pretomanid FGK) (updated)

Pretomanid, Tuberculosis, Multidrug-Resistant
Date of authorisation: 31/07/2020, , , Revision: 9, Authorised, Last updated: 01/12/2023
List item

Human medicine European public assessment report (EPAR): Adcetris (updated)

Brentuximab vedotin, Lymphoma, Non-Hodgkin; Hodgkin Disease
Date of authorisation: 25/10/2012, , Revision: 35, Authorised, Last updated: 01/12/2023
List item

Human medicine European public assessment report (EPAR): Ocaliva (updated)

Obeticholic acid, Liver Cirrhosis, Biliary
Date of authorisation: 12/12/2016, , , , Revision: 17, Authorised, Last updated: 30/11/2023
List item

Human medicine European public assessment report (EPAR): Yuflyma (updated)

adalimumab, Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthritis, Juvenile Rheumatoid
Date of authorisation: 11/02/2021, , Revision: 12, Authorised, Last updated: 30/11/2023
List item

Human medicine European public assessment report (EPAR): Soliris (updated)

Eculizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 20/06/2007, , , Revision: 36, Authorised, Last updated: 30/11/2023
List item

Human medicine European public assessment report (EPAR): Abevmy (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 21/04/2021, , , Revision: 7, Authorised, Last updated: 30/11/2023
List item

Human medicine European public assessment report (EPAR): Riximyo (updated)

rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis; Wegener Granulomatosis
Date of authorisation: 15/06/2017, , Revision: 14, Authorised, Last updated: 29/11/2023
List item

Human medicine European public assessment report (EPAR): Blitzima (updated)

rituximab, Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017, , Revision: 19, Authorised, Last updated: 29/11/2023
List item

Human medicine European public assessment report (EPAR): Rixathon (updated)

rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Wegener Granulomatosis; Microscopic Polyangiitis; Pemphigus
Date of authorisation: 15/06/2017, , Revision: 12, Authorised, Last updated: 29/11/2023
List item

Human medicine European public assessment report (EPAR): Truxima (updated)

rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Wegener Granulomatosis; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopic Polyangiitis
Date of authorisation: 17/02/2017, , Revision: 20, Authorised, Last updated: 29/11/2023
List item

Human medicine European public assessment report (EPAR): Ruxience (updated)

rituximab, Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Microscopic Polyangiitis; Pemphigus
Date of authorisation: 01/04/2020, , , Revision: 11, Authorised, Last updated: 29/11/2023
List item

Human medicine European public assessment report (EPAR): Vyvgart (updated)

Efgartigimod alfa, Myasthenia Gravis
Date of authorisation: 10/08/2022, , , Revision: 5, Authorised, Last updated: 28/11/2023
List item

Human medicine European public assessment report (EPAR): Pirfenidone Viatris (updated)

Pirfenidone, Idiopathic Pulmonary Fibrosis; Lung Diseases; Respiratory Tract Diseases
Date of authorisation: 10/01/2023, , Revision: 1, Authorised, Last updated: 28/11/2023
List item

Human medicine European public assessment report (EPAR): Zessly (updated)

infliximab, Arthritis, Psoriatic; Psoriasis; Crohn Disease; Arthritis, Rheumatoid; Colitis, Ulcerative; Spondylitis, Ankylosing
Date of authorisation: 18/05/2018, , Revision: 12, Authorised, Last updated: 28/11/2023
List item

Human medicine European public assessment report (EPAR): Tecartus (updated)

Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel), Lymphoma, Mantle-Cell
Date of authorisation: 14/12/2020, , , , Revision: 5, Authorised, Last updated: 28/11/2023

Load more

684 results

Human medicine European public assessment report (EPAR): Yesafili (updated)

Human medicine European public assessment report (EPAR): Leflunomide medac (updated)

Human medicine European public assessment report (EPAR): Filgrastim Hexal (updated)

Human medicine European public assessment report (EPAR): Ziextenzo (updated)

Human medicine European public assessment report (EPAR): Clopidogrel Krka (updated)

Human medicine European public assessment report (EPAR): Fulphila (updated)

Human medicine European public assessment report (EPAR): Semglee (updated)

Human medicine European public assessment report (EPAR): Ogivri (updated)

Human medicine European public assessment report (EPAR): Kirsty (previously Kixelle) (updated)

Human medicine European public assessment report (EPAR): Hulio (updated)

Human medicine European public assessment report (EPAR): Dovprela (previously Pretomanid FGK) (updated)

Human medicine European public assessment report (EPAR): Adcetris (updated)

Human medicine European public assessment report (EPAR): Ocaliva (updated)

Human medicine European public assessment report (EPAR): Yuflyma (updated)

Human medicine European public assessment report (EPAR): Soliris (updated)

Human medicine European public assessment report (EPAR): Abevmy (updated)

Human medicine European public assessment report (EPAR): Riximyo (updated)

Human medicine European public assessment report (EPAR): Blitzima (updated)

Human medicine European public assessment report (EPAR): Rixathon (updated)

Human medicine European public assessment report (EPAR): Truxima (updated)

Human medicine European public assessment report (EPAR): Ruxience (updated)

Human medicine European public assessment report (EPAR): Vyvgart (updated)

Human medicine European public assessment report (EPAR): Pirfenidone Viatris (updated)

Human medicine European public assessment report (EPAR): Zessly (updated)

Human medicine European public assessment report (EPAR): Tecartus (updated)